Fig. 8
From: Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease
Synaptic levels of GluA2 are increased in jasplakinolide-treated APP/PS1 neurites. (a) Representative images of jasplakinolide-treated WT and APP/PS1 primary cortical neurons stained with phalloidin, anti-PSD-95 antibody and anti-GluA2 antibody. (b) Quantification of GluA2 levels. (c) Colocalization of PSD-95 and GluA2 quantified using pearson’s correlation coefficient. Statistical comparison between groups were conducted using two-way ANOVA followed by Tukey’s post test. Data are presented as mean ± SEM (n = 3, 15 neurites from each independent experiment). Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Scale bar = 5 μm